candidate, PER-001, is an endothelin receptor antagonist delivered through a sustained-release intravitreal implant for conditions such as glaucoma and diabetic retinopathy. The company’s research and development activities center on ophthalmology, including drug discovery, formulation development, and ocular drug delivery systems. Perfuse Therapeutics also advances intellectual property and clinical programs related to treatments for retinal vascular diseases and neurodegenerative eye disorders. Its platform is designed to address underlying disease mechanisms associated with impaired ocular circulation and progressive blindness.